Hematology · Hemolytic Anemia
The facts most likely to be tested
Press 1–5 to rate · ↑↓ to navigate
The Direct Coombs test (Direct Antiglobulin Test) is the gold standard diagnostic test to confirm the presence of IgG or C3 on the surface of red blood cells.
Warm AIHA is characterized by IgG-mediated hemolysis occurring at body temperature; roughly half of cases are idiopathic (primary), with the classic secondary causes being SLE, CLL, and methyldopa.
Cold Agglutinin Disease is characterized by IgM-mediated hemolysis occurring at low temperatures, whereas the secondary, post-infectious form following Mycoplasma pneumoniae or Epstein-Barr virus is properly termed cold agglutinin syndrome.
Peripheral blood smears in AIHA typically reveal spherocytes due to partial phagocytosis of the red cell membrane by splenic macrophages.
Laboratory findings in AIHA demonstrate elevated LDH, decreased haptoglobin, and elevated indirect bilirubin consistent with extravascular hemolysis.
First-line treatment for Warm AIHA is corticosteroids (prednisone 1 mg/kg/day), with rituximab as the preferred second-line agent and splenectomy reserved for refractory disease.
Management of Cold Agglutinin Disease focuses on avoidance of cold temperatures and treating the underlying lymphoproliferative disorder or infection.
Vignette unlocked
A 62-year-old female with a history of chronic lymphocytic leukemia presents with increasing fatigue and dark-colored urine. Physical examination reveals scleral icterus and splenomegaly. Laboratory studies show a hemoglobin of 8.2 g/dL, elevated LDH, low haptoglobin, and elevated indirect bilirubin. A Direct Coombs test is positive for IgG.
What is the most appropriate initial pharmacologic treatment for this patient's condition?
Corticosteroids
The patient presents with classic signs of Warm AIHA (IgG-mediated), which is treated first-line with corticosteroids to suppress the immune-mediated destruction of red blood cells.
Full handout
High yield triage
Etiology / Epidemiology
Associated with SLE, CLL, and Mycoplasma pneumoniae. Triggered by autoantibodies against RBC surface antigens.
Clinical Manifestations
Presents with jaundice, splenomegaly, and dark tea-colored urine. Look for symptomatic anemia.
Diagnosis
The Direct Coombs test is the gold standard. Expect elevated LDH, low haptoglobin, and reticulocytosis.
Treatment
Corticosteroids are first-line. Do not withhold transfusion in severe or symptomatic anemia — give ABO/Rh-matched units and accept crossmatch incompatibility rather than delay.
Prognosis
High risk of thromboembolism. Monitor for relapse in chronic cases.
Full handout
Epidemiology & Etiology
Warm AIHA is often idiopathic or secondary to lymphoproliferative disorders like CLL. Cold agglutinin disease is frequently triggered by Mycoplasma pneumoniae or Epstein-Barr virus. Incidence increases with age, particularly in patients with underlying autoimmune disease.
Pertinent Anatomy
The spleen serves as the primary site of RBC destruction in warm AIHA. The liver may also contribute to sequestration in severe cases. Cold agglutinin disease involves complement (C3b)-mediated hemolysis that is primarily extravascular, with clearance of opsonized RBCs in the liver.
Pathophysiology
Warm AIHA involves IgG antibodies binding to RBCs at body temperature, leading to extravascular hemolysis in the spleen. Cold agglutinin disease involves IgM antibodies that fix complement at low temperatures, causing predominantly extravascular (C3b-mediated, hepatic) hemolysis, with intravascular hemolysis in severe exacerbations. Intravascular hemolysis releases free hemoglobin, causing hemoglobinemia and hemoglobinuria.
Clinical Manifestations
Patients present with signs of hemolytic anemia including fatigue, dyspnea, and icterus. Physical exam reveals splenomegaly in warm AIHA and acrocyanosis (blue fingers/toes) in cold agglutinin disease. Red flag: rapid onset of hemodynamic instability or dark urine indicates acute massive hemolysis.
Diagnosis
The Direct Coombs test (Direct Antiglobulin Test) is the gold standard for diagnosis. Laboratory findings include elevated LDH, decreased haptoglobin, and indirect hyperbilirubinemia. Peripheral smear shows spherocytes in warm AIHA and agglutinated RBCs in cold agglutinin disease.
Treatment
Initiate Corticosteroids (prednisone) as the first-line treatment for warm AIHA. For refractory cases, rituximab is the preferred second-line therapy, with splenectomy or nipocalimab (anti-FcRn; FDA-approved August 2026 as the first drug specifically indicated for wAIHA in patients 12 years and older previously or currently treated with corticosteroids) as further options. Caution: crossmatching is confounded by panreactive autoantibody, but transfusion must not be delayed in severe anemia — notify the blood bank and transfuse ABO/Rh-matched units. Cold agglutinin disease requires avoidance of cold exposure; corticosteroids and splenectomy are largely ineffective, and rituximab (+/- bendamustine) or the anti-C1s complement inhibitor sutimlimab is used for symptomatic disease.
Prognosis
Patients remain at a significantly increased risk of venous thromboembolism. Long-term management requires monitoring for treatment-refractory anemia and secondary malignancy. Relapse is common, necessitating a slow taper of immunosuppressive therapy.
Differential Diagnosis
Hereditary Spherocytosis: negative Coombs test with family history
G6PD Deficiency: bite cells and blister cells on smear
Paroxysmal Nocturnal Hemoglobinuria: flow cytometry shows CD55/CD59 deficiency
Microangiopathic Hemolytic Anemia: presence of schistocytes
Sickle Cell Disease: hemoglobin electrophoresis confirms diagnosis